Article
Therapeutic mRNA Drug Products Beyond Vaccines — Drug Substance Specifications and Drug Product Stability CMC
Every mRNA CMC program built in the last several years has been built on a vaccine foundation. The IVT process, the LNP formulation platform, the analytical methods, and…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Therapeutic mRNA Drug Products Beyond Vaccines — Drug Substance Specifications and Drug Product Stability CMC
Every mRNA CMC program built in the last several years has been built on a vaccine foundation. The IVT process, the LNP formulation platform, the analytical methods, and…
Article
Oligonucleotide Drug Products — Antisense, siRNA, and Aptamer CMC Under FDA and EMA Review
Oligonucleotide therapeutics have achieved commercial validation — multiple phosphorothioate ASOs, several GalNAc-conjugated siRNAs, and multiple aptamers are FDA-approved, and the pipeline is expanding rapidly. The solid-phase synthesis chemistry…
Article
Peptide Drug Products — CMC Strategy for Synthetic Peptides: From SPPS to Drug Substance Specification
The peptide therapeutics market has expanded dramatically — GLP-1 receptor agonists, integrin antagonists, antimicrobial peptides, cyclic peptides, and stapled peptides are in clinical development across virtually every therapeutic…
Article
Radiopharmaceutical Drug Products — CMC Requirements Under FDA 21 CFR Part 315 and NDABLA Pathways
Radiopharmaceutical CMC shares almost nothing with standard pharmaceutical CMC except the regulatory framework it sits within. The drug substance is a radioisotope — its "purity" is measured in…
Article
Antibody-Drug Conjugate Drug Delivery — CMC for the Linker-Payload Component Beyond DAR Distribution
Every ADC CMC team knows that drug-to-antibody ratio is the critical quality attribute that defines ADC potency and PK behavior. The HIC-HPLC method for DAR determination is well-established.…
Article
Cyclodextrin Inclusion Complexes — Characterization and CMC Strategy for Solubilized Drug Products
Cyclodextrin complexation is one of the oldest and most commercially validated solubilization technologies in pharmaceutical formulation. HP-β-CD was approved as a parenteral excipient in the early 1990s, and…
Article
Exosomes and Extracellular Vesicles as Drug Delivery Systems — CMC at the Biologic-Nanomedicine Interface
Exosome drug delivery is simultaneously one of the most promising and most CMC-challenged platforms in pharmaceutical development. The biology is compelling — endogenous vesicle tropism, immune evasion, and…
Article
Albumin-Bound Nanoparticle Drug Products — CMC Lessons from Abraxane and nab-Paclitaxel Platform
Abraxane was approved in 2005. The nab-technology platform — albumin-bound nanoparticles manufactured by high-pressure homogenization — is one of the most commercially validated nanomedicine platforms in oncology. The…
Article
Liposome Drug Products — CMC State of Practice from Doxil to Onpattro and the Next Generation
Doxil was approved in 1995. Onpattro was approved in 2018. Between them, they bracket over two decades of liposome and lipid nanoparticle regulatory evolution — from the first…
Article
PLGA Microsphere Drug Products — CMC Framework for Long-Acting Injectable Formulations
Long-acting PLGA microsphere formulations are commercially validated — FDA-approved PLGA microsphere LAI products have been on the market since the late 1980s. The polymer degradation mechanism, the emulsion…
Article
Emerging Market Regulatory CMC — China NMPA, India CDSCO, and GCC Country CMC Requirements
China, India, and the GCC countries represent the next several hundred million patients in a global commercial launch plan. None of them accept an FDA NDA Module 3…
Article
ICH S9 and Oncology CMC — Regulatory Science Basis for Reduced CMC Requirements in Oncology Programs
ICH S9 is a nonclinical guideline. It doesn't directly govern your IND CMC package. But its nonclinical flexibility connects directly to your ICH M7 genotoxic impurity control strategy…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.